{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:23:42Z","timestamp":1772573022783,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2005,10,14]],"date-time":"2005-10-14T00:00:00Z","timestamp":1129248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The incidence of hepatocellular carcinoma is increasing, but the temporal changes of risk factors remain unclear. A significant proportion of hepatocellular carcinoma (7\u201330%) develops in cryptogenic cirrhosis, and may represent the most worrisome complication of non\u2010alcoholic steatohepatitis. Non\u2010alcoholic steatohepatitis is tightly related to insulin resistance and several features of the metabolic syndrome, i.e obesity, type 2 diabetes and dyslipidaemia. Nearly two\u2010thirds of adults in the United States and an increasing percentage of the population worldwide are overweight or obese. Diabetes prevalence is increasing as well. The rising prevalence of risk factors associated with non\u2010alcoholic steatohepatitis can partially account for the increasing incidence of cryptogenic cirrhosis and subsequent hepatocellular carcinoma. Moreover, recent evidence demonstrates that both obesity and diabetes are <jats:italic>per se<\/jats:italic> associated with an increased cancer risk. Large prospective studies show a significant association with obesity for several cancers, including cancers of the colon, female breast, endometrium, kidney, oesophagus and liver (hepatocellular carcinoma). Type 2 diabetes is also related with increased risks of colon, endometrial, kidney, pancreatic cancer and hepatocellular carcinoma. In western countries, the insulin resistance syndrome is emerging as a risk factor for a wide variety of cancers, including hepatocellular carcinoma.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02594.x","type":"journal-article","created":{"date-parts":[[2005,10,14]],"date-time":"2005-10-14T14:15:16Z","timestamp":1129299316000},"page":"40-43","source":"Crossref","is-referenced-by-count":53,"title":["Review article: steatosis, the metabolic syndrome and cancer"],"prefix":"10.1111","volume":"22","author":[{"given":"E.","family":"BUGIANESI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,14]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401001"},{"key":"e_1_2_4_3_2","volume-title":"Surveillance, Epidemiology, and End Results (SEER) Program Public\u2010Use CD\u2010ROM (1973\u20131996), National Cancer Institute, DCPC Surveillance Program, Cancer Statistics Branch","author":"National Cancer Institute","year":"1999"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(03)00552-5"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.013"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34168"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360609"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33324"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2003.12.008"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2006.00569.x"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.5.5661"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70364-7"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.1.76"},{"key":"e_1_2_4_14_2","first-page":"371","article-title":"Liver diseases and diabetes mellitus","volume":"3","author":"Creutzfeldt W","year":"1970","journal-title":"Prog Liver Dis"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.5.756"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021423"},{"key":"e_1_2_4_17_2","volume-title":"IARC Handbooks of Cancer Prevention. Weight Control and Physical Activity","author":"IARC","year":"2002"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1408"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:CACO.0000016573.79453.ba"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90254-2"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008995217664"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh041"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04054.x"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.065"},{"key":"e_1_2_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.19.1592"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.13.1147"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.1995.0003"},{"key":"e_1_2_4_28_2","first-page":"302A","article-title":"Leptin is required for the development of hepatic fibrosis","volume":"32","author":"Leclerq IA","year":"2000","journal-title":"Hepatology"},{"key":"e_1_2_4_29_2","first-page":"5016","article-title":"Hepatic hyperplasia in noncirrhotic fatty livers is obesity\u2010related hepatic steatosis a premalignant condition","volume":"61","author":"ShiQi Y","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.2000.1829"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051393"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112780"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702273360907"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.05.029"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00051703"},{"key":"e_1_2_4_36_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008838412423"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0580"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02594.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02594.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:42:25Z","timestamp":1695742945000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02594.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,14]]},"references-count":36,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02594.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02594.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,14]]}}}